Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yishen-Qingli-Huoxue Formula (YQHF) is a Traditional Chinese Medicine herbal formula used for treating chronic kidney disease (CKD) and renal fibrosis. The formula works through multiple mechanisms including inhibiting indoxyl sulfate via the **AhR/snai1 signaling pathway**, reducing fibrotic factors such as smoc2 and cdh11, and antagonizing renal fibrosis. The formula has been validated through clinical randomized controlled trials and has demonstrated effectiveness in improving renal function, reducing proteinuria, and alleviating renal fibrosis in CKD patients[2][5][7]. The mechanisms involve anti-inflammatory effects, inhibition of epithelial-mesenchymal transition, and modulation of metabolic pathways related to uremic toxins.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on yishen-qingli-huoxue formula.